Lazar David E.'s Form 4 filing
Titan Pharmaceuticals Inc (TTNP) · filed Jun 23, 2023
- Accession no.
- 0000921895-23-001569
- Filed
- Jun 23, 2023, 4:07 PM ET
- Trade date
- Jun 21, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $4.61M. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0000921895-23-001593 (Jun 28, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lazar David E.CIK 0001932843 | Director, Officer (Chief Executive Officer), 10% Owner |
| Activist Investing LLCCIK 0001817604 | Other: Member of 10% owner group |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
These Shares were sold pursuant to a Share Transfer Agreement dated June 21, 2023. As consideration for the transfer, Mr. Lazar received $4,600,000.
Referenced by the price of 2 transactions in Table I.